Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, August 2025
Year of Publication2025
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
We recommend not to use ivermectin in patients with severe or critical COVID-19, except in the context of a clinical trial
Recommended against
Strong
Certainty of evidence
Very low
Notes and Remarks
- A recommendation to only use a drug in the setting of clinical trials is appropriate when there is very low certainty evidence and future research has a large potential for reducing uncertainty about the effects of the intervention and for doing so at reasonable cost.
- A strong recommendation against use of ivermectin in patients with non-severe COVID-19 was published in October 2023, given new trial evidence. Practical info The GDG made a recommendation against using ivermectin for treatment of patients with COVID-19 outside the setting of a clinical trial and therefore practical considerations are less relevant for this drug
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Therapeutics and COVID-19: living guideline, 10 November 2023.
Year2023
InstitutionWorld Health Organization